Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease.

Article Details

Citation
Copy to clipboard

Bollard CM, Savoldo B, Rooney CM, Heslop HE

Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease.

Acta Haematol. 2003;110(2-3):139-48. doi: 10.1159/000072463.

PubMed ID
14583674 [ View in PubMed
]
Abstract

Increased understanding of the mechanisms by which T lymphocytes recognize virus and tumor-specific antigens has fueled the use of adoptive immunotherapy for viral and malignant diseases. An ideal candidate for such treatment is Epstein-Barr virus (EBV). EBV-associated post-transplant lymphoproliferative disorder (PTLD) is a serious complication post-solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). The disease is essentially the result of suppression of cytotoxic T-cell function and despite various treatment strategies the course may still be fulminant and lethal. Therefore, an adoptive immunotherapeutic approach using ex vivo derived EBV-specific CTL offers a promising solution not only for the treatment but also as prophylaxis for PTLD. The infusion of EBV-CTL has been demonstrated to be safe and effective in allogeneic HSCT recipients and their use post-SOT is being evaluated.

DrugBank Data that Cites this Article

Drugs